129 related articles for article (PubMed ID: 35347041)
1. Treatment Outcomes in Neuroendocrine Prostate Cancer.
Iwamoto H; Nakagawa R; Makino T; Kadomoto S; Yaegashi H; Nohara T; Shigehara K; Izumi K; Kadono Y; Mizokami A
Anticancer Res; 2022 Apr; 42(4):2167-2176. PubMed ID: 35347041
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.
Eule CJ; Hu J; Al-Saad S; Collier K; Boland P; Lewis AR; McKay RR; Narayan V; Bosse D; Mortazavi A; Rose TL; Costello BA; Bryce AH; Lam ET
Clin Genitourin Cancer; 2023 Aug; 21(4):483-490. PubMed ID: 37193610
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study.
Zhu J; Liang X; Wu D; Chen S; Yang B; Mao W; Shen D
Medicine (Baltimore); 2021 Apr; 100(15):e25237. PubMed ID: 33847621
[TBL] [Abstract][Full Text] [Related]
5. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract][Full Text] [Related]
7. Platinum sensitivity in metastatic prostate cancer: does histology matter?
Humeniuk MS; Gupta RT; Healy P; McNamara M; Ramalingam S; Harrison M; George D; Zhang T; Wu Y; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):92-99. PubMed ID: 29230006
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases.
Zhang Q; Han Y; Zhang Y; Liu D; Ming J; Huang B; Qiu X
Front Oncol; 2020; 10():571308. PubMed ID: 33598420
[TBL] [Abstract][Full Text] [Related]
9. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.
Zaffuto E; Pompe R; Zanaty M; Bondarenko HD; Leyh-Bannurah SR; Moschini M; Dell'Oglio P; Gandaglia G; Fossati N; Stabile A; Zorn KC; Montorsi F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2017 Oct; 15(5):e793-e800. PubMed ID: 28506524
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis.
Wang HT; Yao YH; Li BG; Tang Y; Chang JW; Zhang J
J Clin Oncol; 2014 Oct; 32(30):3383-90. PubMed ID: 25225419
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcomes of Second-Line Systemic Therapy for Neuroendocrine Prostate Cancer: A Report of Four Cases.
Tsubonuma Y; Funakoshi K; Takaba T; Jyojima K; Minato A; Tomisaki I; Harada K; Fujimoto N
J UOEH; 2024; 46(1):23-28. PubMed ID: 38479871
[TBL] [Abstract][Full Text] [Related]
12. Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer.
Mori H; Nakajima K; Kadomoto S; Mizokami A; Ikeda H; Wakabayashi H; Kinuya S
Intern Med; 2018 Nov; 57(21):3123-3128. PubMed ID: 29877274
[TBL] [Abstract][Full Text] [Related]
13. Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases.
Ikeda J; Ohe C; Ohsugi H; Matsuda T; Tsuta K; Kinoshita H
Pathol Int; 2021 Sep; 71(9):621-626. PubMed ID: 34297443
[TBL] [Abstract][Full Text] [Related]
14. Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases.
Pokhrel A; Nair K; Jaswani V; Salyana M; Mooppan U; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221093886. PubMed ID: 35473437
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.
Huang G; Zhang H; Shi H; Zhang W; Wang T; Wang Z; Chen Q; Lian B; Li J; Yang G
World J Surg Oncol; 2022 Dec; 20(1):407. PubMed ID: 36572885
[TBL] [Abstract][Full Text] [Related]
17. [Neuroendocrine prostate cancer].
Kretschmer A; Wittekind C; Stief CG; Gratzke C
Urologe A; 2015 Dec; 54(12):1779-83. PubMed ID: 26582381
[TBL] [Abstract][Full Text] [Related]
18. Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.
Fujimoto N; Tsubonuma Y; Nagata Y; Minato A; Tomisaki I; Harada K; Miyamoto H
Anticancer Res; 2023 Sep; 43(9):3841-3847. PubMed ID: 37648316
[TBL] [Abstract][Full Text] [Related]
19. Clinical Features of Treatment-related Neuroendocrine Prostate Cancer: A Case Series.
Suzuki K; Terakawa T; Jimbo N; Inaba R; Nakano Y; Fujisawa M
Anticancer Res; 2020 Jun; 40(6):3519-3526. PubMed ID: 32487653
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate.
Apostolidis L; Nientiedt C; Winkler EC; Berger AK; Kratochwil C; Kaiser A; Becker AS; Jäger D; Hohenfellner M; Hüttenbrink C; Pahernik S; Distler FA; Grüllich C
Oncotarget; 2019 Jan; 10(1):17-29. PubMed ID: 30713600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
